Drug intelligence / Profile preview

DA5221-B2

Development stage: Phase 4
Lead developer: Dong-A ST
Modality: Small Molecules

Overview

DA5221-B2 is an investigational drug developed by Dong-A ST, currently in clinical development as part of combination therapy for type 2 diabetes. It is described as a DPP-4 inhibitor, intended to improve glycemic control in patients with type 2 diabetes who have inadequate blood glucose control on other therapies. DA5221-B2 is being studied in combination with other agents such as the SGLT-2 inhibitor DA5221-T and another component, DA5221-B1. The mechanism of action involves inhibition of dipeptidyl peptidase-4 (DPP-4), which increases incretin levels and thereby enhances insulin secretion and suppresses glucagon release.

Brand names: Suganon
Other names: evogliptin tartrate

Targets

DPP-4 (Dipeptidyl Peptidase-IV)

Beyond the preview

Go deeper on DA5221-B2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DA5221-B2.

Explore the full profile